Myelin oligodendrocyte glycoprotein (MOG) is localized at the outermost layer of the myelin sheath and is accessible for autoantibodies. Although experimental autoimmune encephalitis induced with MOG immunization has been studied for 30 years, the results of previous reports on MOG immunoglobulin G (IgG) detection with enzyme-linked immunosorbent assay and Western blot are confusing. However, after the development of human MOG-transfected cell-based assay to detect conformational-sensitive MOG-IgG, unique groups of patients have been found seropositive, and MOG-IgG-associated disease has become a hot topic in clinical neuroimmunology. Currently, the clinical spectrum of MOG-IgG-associated disease includes idiopathic optic neuritis, acute disseminated encephalomyelitis, encephalitides (brainstem and cerebral cortical), idiopathic myelitis, atypical multiple sclerosis, aquaporin-4 IgG-negative neuromyelitis optica spectrum disorders and others. MOG-IgG-associated disease occurs in both children and adults, and the female:male ratio is almost 1:1. Pleocytosis in the cerebrospinal fluids during acute exacerbation is often seen, but oligoclonal IgG bands are usually negative. T helper cell 17, B cells and neutrophil-related cytokines appear to be upregulated intrathecally. The pathology of acute lesions is characterized by active inflammation demyelination with deposition of immunoglobulins and complements. Just like aquaporin 4 IgG-positive neuromyelitis optica spectrum disorders, some disease-modifying drugs for multiple sclerosis seem to be inefficacious in MOG-IgG-associated disease, and chronic immunosuppression is required to prevent relapse, especially in patients persistently positive for MOG-IgG. Our understanding of this newly recognized disease remains insufficient, and the progress of research is much expected.
Introduction
Inflammatory diseases of the central nervous system in humans include multiple sclerosis (MS), acute disseminated encephalomyelitis (ADEM), idiopathic optic neuritis and myelitis, Balo's concentric sclerosis and others. [1] [2] [3] [4] Neuromyelitis optica spectrum disorders (NMOSD) had long been considered a member of this clinical entity, but after the discovery of aquaporin-4 (AQP4) immunoglobulin G (IgG), an NMOSD-specific autoantibody, the pathological data on NMOSD has accumulated, and AQP4-IgG-seropositive NMOSD is now recognized as an astrocytopathic disease. 5, 6 Myelin oligodendrocyte glycoprotein (MOG) is a myelin protein, 7, 8 and MOG peptides have been used as an immunogen to induce experimental autoimmune encephalomyelitis (EAE). 9 However, the results of previous studies on human disease for the presence of MOG-IgG detected by enzyme-linked immunosorbent assay and Western blot have been confusing. With cell-based assay (CBA) to detect conformation-sensitive MOG-IgG, a unique group of patients have been found seropositive for the myelin autoantibody. [10] [11] [12] [13] [14] [15] [16] In this article, we present a brief overview of the biology of MOG, MOG-IgG assay, the clinical, neuroimaging and laboratory findings, pathology and pathomechanisms, and therapy of MOG-IgG-associated diseases.
Biology of MOG
MOG is a type I integral membrane protein, and is localized in the extracellular surface of oligodendrocytes and the outermost lamellae of myelin sheath, suggesting that MOG might be accessible for autoantibodies. 7, 8, 17 The extracellular portion has an immunoglobulin-like domain. MOG has monomeric and dimeric species. The primary transcript of the MOG gene has 15 561 nucleotides, and human MOG has 139 amino acids. Human MOG cDNA is homologous to rats, mice, and bovine, and the amino acid sequences are highly conserved among animal species (>90%). The function of MOG is not fully understood, but MOG seems to serve as a homophilic adhesion receptor, and contribute to compaction and maintenance of myelin.
MOG-EAE resembles NMO
MOG is highly immunogenic, and can stimulate both T-and B-cell responses. Such MOG peptides as MOG1-22, MOG35-55 and MOG92-106 are encephalitogenic in EAE, and MOG35-55 can induce various clinical phenotypes of EAE (relapsing-remitting and progressive). MOG-EAE has been studied for 30 years, and is known to mimic human NMO to some extent. 9 Of particular note is a report on spontaneous bilateral optic neuritis and lumbar myelitis closely resembling Devic's disease in a double-transgenic mouse model of autoimmune T-cell/B-cell cooperation (recombination-competent immune cells expressing a T-cell receptor-alpha/beta specific for MOG35-55 peptide in the context of I-Ab along with an immunoglobulin J region replaced by the recombined heavy chain of a monoclonal antibody binding to a conformational epitope on MOG). 18 However, in those days, AQP4-IgG attracted a great deal of attention as a newly-discovered, NMO-specific biomarker, and the MOG story was not so conspicuous in the research of the human disease.
Disappointment at MOG-IgG seropositivity
A number of studies on MOG-IgG with enzymelinked immunosorbent assay, Western blot or immunohistochemistry had been published, but they were not able to reveal a unique group of patients. 10, 16 Later, MOG-IgG took center stage in MS research when the patients with clinically isolated syndrome who were seropositive for both MOG-IgG and myelin basic protein (MBP) IgG in the blood were reported to be highly likely to convert to clinically definite MS. 19, 20 Unfortunately, subsequent studies did not confirm the predictive value of the myelin antibodies.
CBA to detect MOG-IgG
The MOG protein does not retain the native threedimensional structure in enzyme-linked immunosorbent assay or Western blot, and there are some amino acid sequence changes between humans and rodents. Recently, human MOG-transfected CBA was developed to detect conformation-sensitive MOG-IgG, and the CBA was able to identify unique patient groups. [10] [11] [12] [13] [14] [15] [16] Although MOG-IgG seropositivity is greatly influenced by which transfectants and secondary antibodies are used, recent studies have shown that a combination of full-length human MOG-transfected cells and secondary antibody specific to Fc or IgG1 is relatively good to detect unique patient groups. However, false positive and false negative results can occur, and further studies will be required to establish a highly reliable standard assay for MOG-IgG.
As for human MOG-IgG reactivity: (i) the CC 0 -loop of MOG is most commonly recognized; (ii) no epitope spreading occurs over time, and (iii) human MOG-IgG does not recognize rodent MOG, which is important in developing animal models of MOGIgG-associated disease. 21 As some patients with NMO are MOG-IgG-positive, it is interesting to know if there are cases doubly positive for MOG-IgG and AQP4-IgG. In most recent studies with MOG-IgG-CBA, no patients possessed both MOG-IgG and AQP4-IgG, but some doubly positive cases have been reported. 22, 23 Clinical, magnetic resonance imaging and laboratory features
The average age of onset of MOG-IgG-associated disease is approximately 30 years, but it ranges widely from <5 years to >70 years, and the ratio of women to men is almost 1:1. This disease seems to be distributed nationwide and worldwide, but large-scale epidemiological surveys have not been carried out. [24] [25] [26] [27] [28] [29] The clinical spectrum of MOG-IgG-associated disease is shown in Fig. 1 . MOG-IgG assayed by CBA is detectable in some patients with idiopathic optic neuritis, idiopathic myelitis, ADEM, AQP4-IgG-seronegative NMOSD, atypical MS, and brainstem and cerebral cortical encephalitides. At least half of the patients have a relapsing disease (~40 relapses). Generally speaking, the frequency of MOG-IgGpositive cases in the clinical phenotypes appears to be higher in children than in adults. Coexisting other autoimmune disorders are less common in MOG-IgG-positive disease than in AQP4-IgG-positive NMOSD. Nevertheless, such cases are occasionally seen (we experienced a patient positive for both NMDA receptor antibody and MOG-IgG who had recurrent central nervous system demyelinating episodes). 30 In cerebrospinal fluid (CSF) examination during acute exacerbation, pleocytosis (mononuclear cells and polymorphonuclear cells) is often seen, but oligoclonal IgG bands are mostly negative and the IgG index is not high.
Clinical phenotypes of MOG-IgG-associated disease
Case examples of magnetic resonance imaging (MRI) abnormalities are shown in Fig. 2 .
Optic neuritis
Optic neuritis is probably the most common clinical phenotype of MOG-IgG-associated disease. It can be unilateral or simultaneous bilateral, but in contrast to AQP4-IgG-positive optic neuritis, optic chiasmal involvement is rare. 24, 31 In the acute phase, severe visual impairment occurs, but functional recovery is relatively good, and unlike AQP4-IgG-positive optic neuritis, blindness is uncommon in MOG-IgG-positive optic neuritis. Orbital MRI might show hyperintense lesions along the optic nerve with gadolinium enhancement, and the optic nerve is often tortuous as a result of severe swelling. The perineural tissue is often gadolinium enhanced as well. In the chronic phase, the retinal nerve fiber layer thickness measured in optical coherence tomography is thicker in MOG-IgG-associated disease than in AQP4-IgG-seropositive NMOSD, suggesting milder neuronal damage in MOG-IgG-positive optic neuritis.
32
Myelitis MOG-IgG-positive myelitis can be transverse, and approximately half of them are longitudinally extensive (longer than three vertebral segments) on MRI. 24, 33 The cervical and thoracic cord are commonly involved, but as compared with AQP4-IgGpositive myelitis, the lumbosacral region is relatively commonly involved. Sensory disturbance and 
AQP4-IgG-seronegative NMOSD
In adults, patients with definite NMO (optic neuritis + longitudinally extensive transverse myelitis) are mostly AQP4-IgG-positive (~80%), and MOGIgG-positive definite NMO is a minor population (~3%). Meanwhile, in pediatric patients with definite NMO, MOG-IgG might be positive in approximately 40% of the total cases. MOG-IgG-positive NMO is generally milder than AQP4-IgG-positive NMO. 24 Interestingly, among the 17 cases compiled by Gault and Devic in Gault's thesis in 1894, the average onset age was 31 years (range 12~52 years), there were more men than women, optic neuritis was bilateral in 15 patients and the course was monophasic in 14 patients. They are features of MOG-IgG-positive cases rather than AQP4-IgG-positive NMO. Some of the case series might have been MOG-IgG-positive.
Atypical MS
Typical MS cases are largely MOG-IgG-negative. In a study of 50 Japanese cases with AQP4-IgG-negative opticospinal MS, just two were MOG-IgG-positive, but they had some features atypical for MS, such as bilateral optic neuritis, longitudinally extensive transverse myelitis or moderate pleocytosis. 35 In a German study, 5% of MS with severe involvement of the spinal cord, optic nerve or brainstem were MOG-IgG-positive and showed poor responses to multiple disease-modifying drug therapies, although
(e) (f) they were oligoclonal band-positive and had typical brain MRI lesions. 36 Approximately 10% of pediatric MS cases have been reported to develop longitudinally extensive transverse myelitis, and AQP4-IgG-seropositivity in those cases is low relative to adult patients with such long spinal cord lesions. At least a certain percentage of pediatric MS patients might be MOGIgG-positive.
Figure 2 Case examples of magnetic resonance imaging abnormalities of myelin oligodendrocyte glycoprotein (MOG) immunoglobulin-G (IgG)-associated disease. (a) A 47-year-old woman with right optic neuritis (right optic nerve is T2-hyperintense, swollen and tortuous in [i] and [ii]). (b) A 60-year-old woman with cervical myelitis (T2-hyperintense lesion in [i] the upper cervical cord, especially [ii] the right dorsal portion in). (c) A 41-year-old man with behavioral abnormality and diplopia ([i] pontine lesions and [ii] multiple cerebral white matter lesions on fluid-attenuated inversion recovery images). (d) A 42-year-old man with left abducens nerve palsy in (i) and (ii) on fluid-attenuated inversion recovery images. (e)
The brain lesions of relapsing-remitting (RR) MS fulfill the MRI criteria of: (i) at least one lesion adjacent to the body of the lateral ventricle and in the inferior temporal lobe; (ii) the presence of a subcortical U-fiber lesion; or (iii) a Dawson's finger-type lesion, with high sensitivity and specificity, and the criteria is useful to distinguish relapsing-remitting MS from MOG-IgG-associated disease, and AQP4-IgG-positive NMOSD with brain lesions. 37 MOGIgG-associated disease frequently develops fluffy brainstem lesions, often located in the pons and/or adjacent to the fourth ventricle. 38 
Brainstem and cerebral cortical encephalitides
Various brain stem lesions can develop, but area-postrema syndrome manifesting intractable hiccups, nausea and vomiting is less common in MOG-IgG-positive disease than in AQP4-IgG-positive NMOSD.
Recently, we reported MOG-IgG-positive unilateral cerebral cortical encephalitis with epilepsy in adults that is distinct from other known autoimmune encephalitis. 39 The cortical lesions were best shown by fluid-attenuated inversion recovery images. Some of the patients developed optic neuritis as well. Epileptic seizures in those patients were often resistant to anti-epilepsy drug therapy alone, but responded swiftly to high-dose intravenous methylprednisolone. The fluid-attenuated inversion recovery-hyperintense cortical lesions disappeared after several months. We also reported a MOG-IgGpositive patient who initially presented with paraparesis as a result of bilateral medial frontal cortex encephalitis. 40 
Pathology and pathomechanisms
A small number of brain-biopsied cases with MOGIgG-positive tumefactive brain lesions have been reported, and the pathological findings are characterized by so-called MS type II pathology (active inflammatory demyelination with deposition of immunoglobulins and complements). 41, 42 Our studies on cell damage markers in the CSF during acute exacerbations showed that regardless of the clinical phenotypes, the CSF MBP level was high, whereas the CSF-glial fibrillary acidic protein level was not elevated at all, clearly showing that MOG-IgG-positive disease is an inflammatory demyelinating disease, even if the clinical phenotype is NMO. 43, 44 Data on immunological abnormalities in MOGIgG-positive disease are insufficient, but T helper cell 17, B cells and neutrophil-related cytokines seem to be upregulated in the CSF during the acute phase of the disease. 45 Although pathogenicity of MOG-IgG has not been clarified, there have been some reports supporting it. An Australian group showed that MOG-IgG affected oligodendrocyte cytoskeleton. 46 MOG-IgG derived from an NMO patient caused reversible lesions in the mouse brain (independent of complement). 47 More recently, a study from Denmark showed that MOG-IgG and complement was sufficient to induce central nervous system demyelination, and was dependent on type I interferon signaling. 48 In fact, the major IgG subclass of MOG-IgG is IgG1, and thus MOG-IgG can efficiently activate complements.
Treatment
Therapy for MOG-IgG-positive disease has not been established and existing evidence is very limited. However, in the acute phase, as with MS and NMOSD, the first-line therapy is intravenous methylprednisolone and most patients respond well, but if refractory to intravenous methylprednisolone, plasma exchange should be started as a rescue therapy. 14, 25, 49 Immunosuppression (corticosteroid, mycophenolate mofetil, methotrexate etc.) is the mainstay for treatment to prevent relapse. 25, 46 In common with AQP4-IgG-positive NMOSD, diseasemodifying drugs for MS, such as like interferon-beta and fingolimod, might not be efficacious in MOGIgG-positive patients. 50, 51 The persistence of MOG-IgG might be crucial for relapse of MOG-IgG-associated disease, and useful in considering relapse prevention. Meanwhile, MOGIgG is only transiently positive in some patients, and the disease in those patients tends to be monophasic. Curiously, a fraction of patients persistently positive for MOG-IgG might also be relapse-free without chronic immunosuppression for over a long period of time. Long-term follow-up data should be accumulated to address the issue. The other authors report no conflict of interest.
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